What is the market's earnings forecast for CTS next quarter?

What is CTS's latest dividend and current dividend yield?

What is CTS's gross profit margin?

What were the key takeaways from CTS’s earnings call?

Did CTS beat or miss consensus estimates last quarter?

What were the key takeaways from CTS's earnings call?

What guidance did CTS's management provide for the next earnings period?

What is the revenue and EPS growth rate for CTS year over year?

- **Diversified Growth Engine**: Diversified end markets (59% of revenue) led by medical (+22% YoY) and aerospace/defense (+23% YoY) offset transportation softness.
- **SyQwest Momentum**: $8.8M Q3 SyQwest sales with $5M+ defense contract and pipeline for 2026 platform awards.
- **Tax Headwind**: U.S. tax legislation reduces EPS by $0.03/share, expected to persist in 2026.
- **Technological Innovation**: Launch of COBROS motor control platform and e-brake technology for EVs/Hybrids.
- **2026 Outlook**: Medical therapeutics and portable diagnostics growth, with cautious optimism on 15M North American light vehicle production.

**【Management Opening Remarks】**
- Q3 2025 sales of $143 million (+8% YoY), with diversified end market sales up 22% YoY, accounting for 59% of total revenue.
- Gross margin expanded by 66 bps to 38.9%, driven by operational efficiency and cost control.
- Secured a $5 million sole-source naval defense contract with SyQwest and $130 million in transportation wins.
- Book-to-bill ratio slightly above 1, with strong bookings in industrial (+29% YoY) and aerospace/defense (+23% YoY).

**【CEO Commentary】**
- Medical sales grew 22% YoY, with 8% QoQ bookings increase, driven by therapeutic products and new ultrasound applications.
- Aerospace/defense sales up 23% YoY, with SyQwest contributing $8.8 million and 29% YoY bookings growth.
- Transportation sales down 7% YoY due to commercial vehicle softness, but wins in Europe/South America and new e-brake technology launch.
- Guidance: 2025 sales $535-545M, EPS $2.20-2.25, with 2026 light vehicle production expected at 15M units in North America.

**【CFO Financial Commentary】**
- Adjusted EPS $0.60 (-2% YoY) due to U.S. tax legislation impact of $0.03/share.
- Operating cash flow $29M, with $17M share repurchases and $110M cash balance.
- Tax rate expected 21-23%, with ongoing adverse impact from legislative changes.
- SG&A up due to $4.2M EPA-related reserve and equity compensation adjustments.

**【Q&A Highlights】**
- Tax impact on EPS to persist in 2026, but industrial recovery and medical bookings strength offset transportation headwinds.
- SyQwest expected to maintain momentum, with potential $5M+ platform awards over 12 months.
- Tariff mitigation strategies include regional production and customer cost-sharing.
- 2026 outlook: diversified end markets (medical, aerospace) to drive growth, while monitoring EV/hybrid adoption trends.

CTS Corporation (CTS) Q3 2025 Earnings Call Transcript

- **Revenue Growth**: Q2 sales $135M (+4% YoY), with diversified markets (55% of revenue) driving 13% YoY growth.
- **Profitability**: Adjusted EBITDA 23% (up 250bps QoQ), gross margin 38.7% (up 296bps YoY).
- **Medical Momentum**: Therapeutic products +60% YoY, offsetting diagnostic softness; overall medical growth expected in 2025.
- **Transportation Challenges**: Sales down 6% YoY due to China, but strong pipeline for e-brake and sensor products.
- **Guidance**: FY2025 sales $520-550M, EPS $2.20-2.35, reflecting cautious outlook on transportation recovery.

**【CEO Summary Section】**
- Q2 2025 revenue: $135 million (+4% YoY), with diversified end markets (medical, aerospace/defense, industrial) accounting for 55% of total sales.
- Adjusted EBITDA expanded 250bps sequentially and 130bps YoY, driven by diversification strategy and operational efficiency.
- Medical sales +8% YoY, with therapeutic products up 60% but diagnostic bookings down 10% due to softness in Asia.
- Aerospace/Defense sales +34% YoY (including $4.5M from SyQwest acquisition); Industrial sales +6% YoY.
- Transportation sales down 6% YoY due to China market dynamics, though pipeline for e-brake and sensor products remains strong.

**【CFO Financial Commentary】**
- Adjusted gross margin: 38.7% (up 296bps YoY), benefiting from diversification and operational improvements.
- Operating cash flow: $28M (vs. $20M YoY), with $99M cash balance and $38M remaining under share buyback program.
- FY2025 guidance: Sales $520-550M, adjusted EPS $2.20-2.35, reflecting cautious outlook on transportation market.

**【Q&A Highlights】**
- **Medical Market**: Therapeutic growth offset short-term diagnostic softness; expect overall medical growth for 2025.
- **Tariffs Impact**: Minimal in Q2, but monitoring USMCA changes.
- **SyQwest Integration**: Pipeline strong, with revenue expected to improve in H2 2025.
- **Acquisition Strategy**: Focused on $50-100M deals in diversified end markets, aiming for 5% organic + 5% acquisition growth.

CTS Corporation (CTS) Q2 2025 Earnings Call Transcript

- **Medical Growth Driver**: Medical sales +13% YoY, book-to-bill 1.3x, ultrasound and therapeutic product wins.
- **Defense Expansion**: Aerospace/defense +39% YoY, SyQwest pipeline up 32% YoY, H2 2025 revenue acceleration.
- **Tariff Resilience**: Mexico-USMCA exemption protects 80% of manufacturing, minimal Q1 tariff impact.
- **Margin Outlook**: Diversified markets (37%+ margins) growing 14% YoY vs transportation (25% margins) down 12%.
- **Key Risks**: China market softness (-12% transportation sales), hybrid/EV adoption rates, 25% vehicle tariffs.

**【CEO Opening Remarks】**
- Q1 2025 revenue of $126M flat YoY, with diversified markets (medical, aerospace/defense, industrial) up 14% to 53% of total sales. Transportation sales down 12% due to China market dynamics.
- Book-to-bill ratio of 1.17 (vs 1.07 Q1 2024), with diversified markets at 1.28. Medical bookings up 30% YoY driven by ultrasound and therapeutics.
- Aerospace/defense sales +39% YoY (SyQwest acquisition +8% organically), with strong pipeline in sonar, non-destructive testing, and RF anti-jamming.
- Industrial sales +4% YoY, with gradual recovery in distribution and OEMs. Transportation expects production volumes down in 2025 due to tariffs.
- Guidance: FY25 sales $520-550M, adj. EPS $2.20-2.35. SyQwest revenue expected to strengthen in Q2 and H2.

**【CFO Financial Highlights】**
- Adj. diluted EPS $0.44 (flat vs Q1 2024). Gross margin 37% (+77bps YoY, -63bps QoQ). Operating cash flow $16M, free cash flow $11M.
- SG&A up $2.3M YoY due to SyQwest acquisition costs and equity comp. Capital expenditures ~4% of sales.
- $7M share buybacks in Q1, $55M remaining under repurchase program. Net debt $87M, cash $90M.

**【Q&A Key Takeaways】**
- **Tariff Impact**: Minimal Q1 impact, but monitoring potential 25% vehicle tariffs. Mexico-USMCA exemption protects 80% of manufacturing.
- **Profitability**: Diversified markets (37%+ margins) growing faster than transportation (25% margins). SyQwest seasonality to boost H2 margins.
- **New Products**: Next-gen commercial vehicle actuator launching Q2, eBrake samples in process. Vehicle footwell win with North American OEM.
- **Defense Pipeline**: SyQwest orders up 32% YoY, with sonar, temperature sensing, and RF anti-jamming wins. H2 2025 revenue expected to accelerate.
- **China Risk**: Transportation sales down 12% YoY due to China market dynamics. Monitoring hybrid/EV penetration rates.
- **Liquidity**: Strong balance sheet with $90M cash, no near-term debt maturities.

CTS (CTS)-30 Apr 25-2025 Q1 Earnings call transcript

- **Revenue Resilience**: Diversified markets drove 28% YoY growth, offsetting transportation decline. Full year gross margin +243bps to 37.2%.
- **Strategic Acquisitions Paying Off**: SyQwest contributed $14M in 2024, with 2025 revenue expected to track acquisition plan.
- **eBrake Momentum**: Predevelopment win with European OEM, targeting 2027-2028 launch with $5-10M first-year revenue.
- **Cash Generation Strong**: $99M operating cash flow in 2024, $48M returned to shareholders via buybacks and dividends.
- **Key Risks**: Tariff uncertainty, China transportation market softness, and delayed OEM decisions on eBrake adoption.


**【CEO Summary Section】**
- **Revenue Performance**: Q4 2024 sales of $127 million (+2% YoY), full year $516 million (-6% YoY). Diversified markets (medical, aerospace, industrial) accounted for 56% of Q4 revenue, up 28% YoY, while transportation sales declined 18% YoY.
- **Strategic Wins**: Six wins in electrification, $70 million in medical sales (+3% YoY), and 37% growth in aerospace/defense to $70 million. SyQwest acquisition contributed $11M in Q4 and $14M annually.
- **Gross Margin Improvement**: Full year adjusted gross margin up 243bps to 37.2%, driven by end-market mix and operational efficiency.
- **2025 Outlook**: Sales $520-550M, EPS $2.20-2.35. Diversified markets expected to grow 7-8%, offsetting transportation headwinds. SyQwest revenue to be stronger in H2.

**【CFO Financial Commentary】**
- **Q4 Financials**: Adjusted EPS $0.53 (+14% YoY), full year $2.17 (-2.3%). Operating cash flow $26M (Q4) and $99M (FY24), up 11% YoY. Free cash flow $76M after capex.
- **Balance Sheet**: $94M cash, $91M long-term debt, $61M remaining under share buyback program. Returned $48M to shareholders in 2024.
- **Key Drivers**: Favorable end-market mix (+243bps margin), operational improvements, and $2.1M FX benefit.

**【Q&A Highlights】**
- **Tariff Impact**: Proactively managing supply chains, with Mexico and China as key focus areas. No single factory at immediate risk.
- **SyQwest Contribution**: Full year 2025 revenue expected to track acquisition plan, with H2 weighting due to U.S. government funding timing.
- **Industrial Recovery**: Sequential growth in Q4 (+2%), with normalized inventory levels supporting gradual 2025 recovery.
- **eBrake Progress**: Predevelopment award with European OEM, targeting $5-10M in first-year revenue post-2027 launch. Long-term growth potential in light vehicles.
- **Commercial Vehicle Market**: Softness expected in 2025, with new actuator production starting Q2 but offset by competition.


CTS

CTS fundamentals

Earnings Call

You can ask Aime